LABORIE Medical Technologies Enters into Strategic Partnership with Urotronic

Laborie Medical Technologies Inc signed a definitive agreement and entered into a multi-faceted, strategic partnership with Urotronic Inc, a Minnesota-based medical device company currently conducting clinical trials to support regulatory approval of Optilume™, a drug-coated balloon (DCB) technology for use in urethral strictures and benign prostatic hyperplasia (BPH). Optilume™ was recently granted CE Mark approval for use in urethral strictures.

The Optilume™ paclitaxel-coated balloon technology was developed in response to patient and physician dissatisfaction with current solutions for urethral strictures and BPH. This innovative, proprietary technology represents a paradigm change from the methods currently used by urologists to treat these conditions and provides a low cost, minimally invasive treatment option for millions of patients suffering from these conditions globally.

Under the terms of the agreement, LABORIE will invest $15 million USD in Urotronic’s Series C financing along with $5 million USD from current shareholders and secure an option to acquire all rights to Optilume™. Under the terms of the option agreement, LABORIE can acquire a perpetual, exclusive license to the Optilume™ Urethral Strictures device, upon FDA approval, for $165 million.  LABORIE also has an option to acquire the Company, upon FDA approval of the Optilume™ BPH device, for $350 million upfront plus another $150 million in earnouts if certain sales milestones are reached.  This strategic partnership with Urotronic demonstrates LABORIE’s continued commitment to expand the use of less invasive treatments and improve outcomes for patients suffering from urological disorders.

Michael Frazzette, President & CEO, LABORIE Says: “Optilume™ is a disruptive, minimally invasive technology that has the potential to change the standard of care for urethral strictures and for BPH. This innovative technology meets multiple unmet medical needs in the market, expands LABORIE’s current urology offering, and aligns well with our desire to help clinicians improve their patients’ lives, With this investment, we are able to support innovation in the urology market and enhance our own product offering for physicians.”

David Perry, President & CEO, Urotronic Says: "We are excited to have LABORIE invest in our company and become a global distribution partner to commercialize our disruptive technologies, Optilume™ offers physicians a device that has the potential to lift the burdens of current treatments. The investment by LABORIE, a leader in urology care globally, strengthens Optilume’s position as a cutting-edge product in the urology device market.”

Doug Kohrs, Board Member, Urotronic Says: “Over the last four years, Urotronic founder Lixiao Wang and his talented team have made impressive progress towards clinically documenting the performance of the Optilume™ technology. In the years ahead, patients all over the globe will have the opportunity to benefit from all the research, development and clinical effort that has been invested in this technology.”

Yuriy Prilutskiy, Managing Director, Patricia Industries, a part of Investor AB Says: “Patricia Industries is committed to supporting the LABORIE and Urotronic teams in their mission to bring Optilume™ to urologists and their patients around the world and help them overcome some of their greatest clinical challenges, This transaction further supports LABORIE’s long-term growth and aligns with our organization’s purpose of creating value for people and society by building strong and sustainable businesses.”

Related Posts

Subscribe Our Newsletter